The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05259917
Recruitment Status : Completed
First Posted : March 2, 2022
Last Update Posted : January 31, 2024
Information provided by (Responsible Party):
KalVista Pharmaceuticals, Ltd.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : December 31, 2023
Actual Study Completion Date : December 31, 2023
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 June 12, 2024